“Recognising gender difference is essential for Parkinson’s research”
Women and Parkinson's
Author: Marina PicilloPublished: 5 December 2019
Prep: Cook: Serves:
In the sixth in our Women and Parkinson’s series, Italian neurologist Marina Picillo shares her findings from studies focussing on gender differences in Parkinson’s, highlights the role cultural bias plays in the results – and reflects on how research into such differences is a relatively “new phenomenon”
I started working in Parkinson’s research when I was in medical school, and developed an interest in gender differences within the condition about six years ago. I began looking into how non-motor symptoms affect men and women differently – with one study revealing that despite women experiencing higher rates of anxiety, depression and panic attacks than men, they remain largely untreated. Men and women experience very different problems. Recognising that is essential for Parkinson’s research purposes – and to ensure better treatment for patients.
The acknowledgment of gender differences in the medical field is quite a new phenomenon – it only started about 30 years ago. It took a while until it filtered down into Parkinson’s research, and I think we are still a little bit behind compared to other research fields. This is probably because two thirds of people with Parkinson’s are men and so the data is dramatically driven by men. But the mentality is changing. The design of studies and the treatment of patients is slowly being given more thought as researchers, the media and the patients themselves call for change.
Diagnostic delays and dyskinesia
Throughout my research I have come across a number of issues that are specific to women. Women are more prone to developing dyskinesia – uncontrollable, involuntary movements that can be a side-effect of levodopa. Some data suggests this is because women have a lower body weight than men, and clinicians prescribe the same dose regardless. Our follow up studies aim to find out more about the metabolism rate of levodopa as we believe that will be different according to gender. If that’s the case, it could seriously impact the way clinicians prescribe the drug in the future.
There’s also the ‘diagnostic delay’ to consider. According to research, on average women are diagnosed a few years later than men. There are a few explanations for this. Parkinson’s is not only less frequent in women, but also appears later in women than men. This is because oestrogen, the primary female sex hormone, is thought to play a ‘protective role’ in the development of Parkinson’s.
Women also generally visit specialists later than men. This may be because they pay less attention to themselves and their health as caregivers. Generally they’re likely to be less involved with their own care – which is an important psychosocial aspect to think about.
I was recently involved in a study which showed that an active sex life improves motor and non-motor symptoms – and quality of life – in people with Parkinson’s, although the results actually only applied to men. This is due to two things. One, women were simply less represented in the study than men. And generally women are less willing to talk about sexual issues than men due to cultural bias.
Women as caregivers
The next topic I’d like to focus my research on is why women are less likely to undergo complex treatments like deep brain stimulation (DBS). It’s a paradox, since women experience worse motor and non-motor fluctuations and more disabling dyskinesia. I think cultural reasons are once more at play here. Generally, worldwide, women have a central role in caring for their families. When a woman is sick, or has to take time off, this impacts on the whole family and causes difficulties. I would like to find out more about why women feel like this, and why there is such a gap in the uptake of these beneficial treatments.
More widely, I would like to see more research into women with young onset Parkinson’s – particularly for those who might still be thinking about having children. There is very little research available on this subject currently.
Though there aren’t symptoms that are unique to women, there are certainly issues that are unique to women with Parkinson’s. There has been progress, and everything is changing – but we still have some way to go.
Need to know: Marina Picillo is a researcher at the Centre for Neurodegenerative Diseases at the University of Salerno, Italy and has authored over 40 research papers. She completed a clinical and research fellowship at the University of Toronto, Canada, where she worked with advanced treatments for Parkinson’s such as DBS.
Parkinson’s and research: the facts
Motor fluctuations, including levodopa-induced dyskinesia, are more common in women with Parkinson’s
Women with Parkinson’s experience a more rapid disease progression than men – and a lower survival rate
Women with Parkinson’s report higher rates of depression and anxiety than men
Women and Parkinson’s: Our campaign
It is estimated that three million women worldwide are living with Parkinson’s – yet their specific needs and experiences are often ignored, leading to disparities in diagnosis, treatment and medication. Each week, we’ll be sharing the little-heard stories of women with the condition to find out how their lives are being affected by a shocking data gap when it comes to women and Parkinson’s. This is just the start.
We want to raise awareness of women’s experience of the condition within the medical profession, so that women’s symptoms are taken seriously.
We think more research is needed into the impact of Parkinson’s on women, so that they can benefit from tailored medication and treatment.
We want to explore ways to offer better support for those women managing the condition alongside caring responsibilities.
Join us – #WomenAndParkinsons.
For more information on women and Parkinson’s please visit the EPDA website.
If you have a story to tell about being a woman with Parkinson’s – or some information about the impact of the condition on women for us to share with the global Parkinson’s community – please get in touch.
A look at Parkinson’s KinetiGraph, a new objective measurement device
4 days ago
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.
‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia
Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”